Vivimed Labs Limited
Vivimed Labs Limited (VIVIMEDLAB) financial statements and selected valuation metrics from NSE/BSE exchange filings through 31 March 2026.
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
Key metrics
Price as of 2026-09-02
Stock price
₹6.67
Market cap
55 Cr
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 35 Cr | 34 Cr | 41 Cr | 39 Cr | 29 Cr | 25 Cr | 37 Cr | 26 Cr | 21 Cr | 21 Cr | 16 Cr | 12 Cr |
| Operating expenses (approx.) | 36 Cr | 40 Cr | 40 Cr | 67 Cr | 33 Cr | 25 Cr | 35 Cr | 28 Cr | 22 Cr | 22 Cr | 27 Cr | 151 Cr |
| EBITDA | -0.33 Cr | -6 Cr | 1 Cr | -28 Cr | -4 Cr | -0.64 Cr | 1 Cr | -2 Cr | -0.28 Cr | -0.95 Cr | -11 Cr | -139 Cr |
| OPM % | -0.9% | -17.5% | 3.1% | -73.7% | -13.4% | -2.6% | 2.9% | -7.8% | -1.3% | -4.6% | -68.3% | -1159.9% |
| Other income | 0.11 Cr | 2 Cr | 0.04 Cr | 8 Cr | 0.06 Cr | 0.03 Cr | 0.07 Cr | 4 Cr | 0.38 Cr | 0.21 Cr | 0 Cr | 6 Cr |
| Interest | 11 Cr | 12 Cr | 13 Cr | -33 Cr | 0.30 Cr | 0.43 Cr | 0.48 Cr | 2 Cr | 0.58 Cr | 2 Cr | 1 Cr | 0.95 Cr |
| Depreciation | 5 Cr | 5 Cr | 5 Cr | 6 Cr | 4 Cr | 4 Cr | 7 Cr | 6 Cr | 5 Cr | 5 Cr | 5 Cr | 12 Cr |
| Profit before tax | -16 Cr | -20 Cr | -17 Cr | 7 Cr | -8 Cr | -5 Cr | -6 Cr | -5 Cr | -5 Cr | -7 Cr | -17 Cr | -146 Cr |
| Tax % | 0.0% | 0.0% | 3.3% | 20.9% | 0.0% | 0.0% | 0.0% | -2.2% | 0.0% | 0.0% | 0.0% | -0.1% |
| Net profit | -16 Cr | -20 Cr | -16 Cr | 5 Cr | -8 Cr | -5 Cr | -6 Cr | -5 Cr | -5 Cr | -7 Cr | -17 Cr | -146 Cr |
| EPS (₹) | ₹1.88 | ₹-2.45 | ₹-1.24 | ₹0.64 | ₹-0.99 | ₹-0.60 | ₹-0.72 | ₹-0.67 | ₹-0.66 | ₹-0.88 | ₹-0.88 | ₹-17.74 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2019 | Mar 2020BSE balance sheet (this exchange's own filing had none for this period) | Mar 2021BSE balance sheet (this exchange's own filing had none for this period) | Mar 2022BSE balance sheet (this exchange's own filing had none for this period) | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,315 Cr | 1,059 Cr | 861 Cr | 237 Cr | 187 Cr | 149 Cr | 116 Cr | 70 Cr | Sign in for TTM |
| Operating expenses (approx.) | 1,138 Cr | 1,051 Cr | 838 Cr | 245 Cr | 374 Cr | 182 Cr | 129 Cr | 221 Cr | Sign in for TTM |
| EBITDA | 177 Cr | 8 Cr | 24 Cr | -8 Cr | -187 Cr | -33 Cr | -13 Cr | -151 Cr | Sign in for TTM |
| OPM % | 13.5% | 0.8% | 2.8% | -3.4% | -100.1% | -22.4% | -10.8% | -216.2% | Sign in for TTM |
| Other income | 23 Cr | 8 Cr | 10 Cr | 1 Cr | 0.97 Cr | 10 Cr | 4 Cr | 6 Cr | Sign in for TTM |
| Interest | 67 Cr | 59 Cr | 54 Cr | 40 Cr | 36 Cr | 2 Cr | 3 Cr | 4 Cr | Sign in for TTM |
| Depreciation | 67 Cr | 67 Cr | 55 Cr | 18 Cr | 108 Cr | 20 Cr | 20 Cr | 26 Cr | Sign in for TTM |
| Profit before tax | 123 Cr | -109 Cr | -76 Cr | -65 Cr | -331 Cr | -46 Cr | -31 Cr | -175 Cr | Sign in for TTM |
| Tax % | 7.0% | 0.3% | -2.7% | -4.3% | 0.6% | 0.8% | -0.4% | -0.1% | Sign in for TTM |
| Net profit | 115 Cr | -109 Cr | -78 Cr | -68 Cr | -329 Cr | -45 Cr | -31 Cr | -175 Cr | Sign in for TTM |
| EPS (₹) | ₹6.95 | ₹-13.16 | ₹-18.76 | ₹-8.16 | ₹-39.62 | ₹-5.48 | ₹-3.85 | ₹-21.15 | Sign in for TTM |
| Dividend payout % | — | — | — | — | — | — | — | — | Sign in for TTM |
Sign in for TTM
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2019 | Mar 2020BSE balance sheet (this exchange's own filing had none for this period) | Mar 2021BSE balance sheet (this exchange's own filing had none for this period) | Mar 2022BSE balance sheet (this exchange's own filing had none for this period) | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 17 Cr | 17 Cr | 17 Cr | 17 Cr | 17 Cr | 17 Cr | 17 Cr | 17 Cr |
| Reserves | 602 Cr | 493 Cr | 415 Cr | 348 Cr | 23 Cr | -22 Cr | -52 Cr | -227 Cr |
| Borrowings | 757 Cr | 889 Cr | 253 Cr | 278 Cr | 379 Cr | 377 Cr | 847 Cr | 397 Cr |
| Other liabilities | 628 Cr | 486 Cr | 605 Cr | 623 Cr | 570 Cr | 579 Cr | 109 Cr | 567 Cr |
| Total liabilities | 2,329 Cr | 2,210 Cr | 1,289 Cr | 1,266 Cr | 988 Cr | 951 Cr | 921 Cr | 753 Cr |
| Fixed assets (net) | 662 Cr | 698 Cr | 348 Cr | 363 Cr | 278 Cr | 263 Cr | 254 Cr | 237 Cr |
| CWIP | 122 Cr | 89 Cr | 60 Cr | 40 Cr | 21 Cr | 21 Cr | 17 Cr | 18 Cr |
| Investments | 305 Cr | 86 Cr | 199 Cr | 199 Cr | 199 Cr | 168 Cr | 168 Cr | 181 Cr |
| Loans & advances | 76 Cr | 79 Cr | 95 Cr | 100 Cr | 40 Cr | 41 Cr | 95 Cr | 21 Cr |
| Inventories | 564 Cr | 502 Cr | 256 Cr | 241 Cr | 80 Cr | 64 Cr | 59 Cr | 13 Cr |
| Trade receivables | 356 Cr | 249 Cr | 108 Cr | 87 Cr | 77 Cr | 83 Cr | 74 Cr | 45 Cr |
| Cash & bank | 95 Cr | 50 Cr | 6 Cr | 7 Cr | 4 Cr | 2 Cr | 0.21 Cr | 0.07 Cr |
| Other assets | 149 Cr | 456 Cr | 217 Cr | 230 Cr | 291 Cr | 309 Cr | 252 Cr | 239 Cr |
| Total assets | 2,329 Cr | 2,210 Cr | 1,289 Cr | 1,266 Cr | 988 Cr | 951 Cr | 921 Cr | 753 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2019 | Mar 2020BSE balance sheet (this exchange's own filing had none for this period) | Mar 2021BSE balance sheet (this exchange's own filing had none for this period) | Mar 2022BSE balance sheet (this exchange's own filing had none for this period) | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | — | — | — | -658 Cr | 14 Cr | -24 Cr | -11 Cr | 8 Cr |
| Cash from investing | — | — | — | 523 Cr | -0.99 Cr | 28 Cr | 5 Cr | -0.95 Cr |
| Cash from financing | — | — | — | -10 Cr | -16 Cr | -6 Cr | 5 Cr | -6 Cr |
| Net cash flow | — | — | — | -139 Cr | -3 Cr | -2 Cr | -1 Cr | 0.65 Cr |
| Free cash flow (OCF − Capex) | — | — | — | -658 Cr | 13 Cr | -24 Cr | -11 Cr | 8 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2019 | Mar 2020BSE balance sheet (this exchange's own filing had none for this period) | Mar 2021BSE balance sheet (this exchange's own filing had none for this period) | Mar 2022BSE balance sheet (this exchange's own filing had none for this period) | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| ROCE % | 11.2% | -2.9% | -3.2% | -3.9% | -70.5% | -14.4% | -4.0% | -95.0% |
| ROE % | 12.2% | 0.0% | -18.0% | 0.0% | -831.9% | — | — | — |
| Debtor days | 99 | 86 | 45 | 134 | 149 | 203 | 232 | 236 |
| Inventory days | 365 | 379 | 261 | 573 | 264 | 261 | 370 | 141 |
| Days payable | 191 | 171 | 35 | 100 | 230 | 180 | 248 | 589 |
| Cash conversion cycle | 273 | 294 | 271 | 607 | 184 | 284 | 354 | -213 |
| Debt / equity | 1.22 | 1.75 | 0.59 | 0.00 | 9.60 | 0.00 | — | — |
| Current ratio | 1.38 | 1.27 | 1.55 | 1.36 | 0.78 | 0.83 | 0.80 | 0.37 |
| Net debt / EBITDA | 3.74 | 0.00 | 0.00 | — | — | — | — | — |
Compare with peers
Loading peers…